Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus IMPEKLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus IMPEKLO.
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER vs IMPEKLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death. At high concentrations, it may also directly damage fungal membranes.
IMPEKLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, reducing activation and release of mediators in allergic responses.
200 mg IV loading dose, then 100-200 mg IV once daily; for invasive candidiasis, 800 mg IV loading dose then 400 mg IV once daily.
IMPEKLO is not a recognized pharmaceutical agent. No dosing information available.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function; prolonged to 98 hours in end-stage renal disease, requiring dose adjustment.
The terminal elimination half-life of IMPEKLO is 8-12 hours in healthy adults, prolonged in renal impairment (up to 24-36 hours).
Approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 11% is excreted as metabolites in urine; fecal excretion accounts for less than 5%.
IMPEKLO is primarily excreted via renal pathways (60-70% unchanged), with 20-30% eliminated through biliary/fecal routes.
Category C
Category C
Antifungal
Antifungal